Lilly brain cancer drug promising in small study

	Tweet

Eli Lilly and Co. said on Tuesday a midstage study of a brain cancer drug helped shrink tumors with minimal side effects.

Lilly said the compound, enzastaurin, is the first targeted agent to enter into late-stage clinical development. The pill is aimed at stopping blood flow to tumors in glioblastoma, a type of brain cancer that affects the central nervous system.

The phase II study included 92 patients with recurrent brain tumors who had failed more than one round of chemotherapy. 

Preliminary results from the study showed 20 percent to 25 percent of patients responded to the drug, with the most common side effect being thrombocytopenia, or low platelet count.

Lilly said final results from the mid-stage study are expected by 2006, and the company is designing a late-stage study of the drug to confirm its safety and effectiveness in a bigger pool of patients. 

RELATED STORIES:
Scientists announce new advance with potential for future cancer targeting   Technology uses tobacco plants to fight cancer   U.S. study faults aggressive end-of-life cancer care   Biomarkers Allow Doctors to Match Therapy to Patient   Herbal remedy shown to have anti-cancer effect   Late-Breaking Science and Clinical Trials   Many Complex Linkages Between Smoking and Cancer   Scientists Identify Cancer Virus’ Genetic Targets   New Study Begins for Kids With High-Risk Cancer   Workers in No-Smoking Restaurants Show Lower Carcinogen Levels   Green Tea Blocks Benefits Of Cancer Drug   Cancer patients want info on costly drug options   Children could be saved from neuroblastoma using antibody therapy   Stem-Cell Sentry Sounds the Alarm to Maintain Balance Between Cancer and Aging   Search for cancer genes unlikely to be successful   Drug combo boosts Pancreatic cancer survival - study   Stress before cancer therapy could help deadly cells survive treatment, lead to disease recurrence   Body Weight, Diet May Be Risk Factors for Non-Hodgkin Lymphoma   Mistletoe extract may treat bladder cancer   Viruses against cancer   African Americans still have higher cancer fatality rate   New Synthetic Form of Protein Holds Promise to Stop Cancer Spread

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]